Eris Lifesciences Q2 Results FY27: PAT Jumps 39.17% to Rs 187.14 Cr, Revenue Rs 892.37 Cr

Eris Lifesciences Ltd (ERIS) Q2 Results FY27 announced on 26 October 2026, covering the company's financial performance for the July to September quarter. Consolidated revenue of Rs 892.37 Cr and net profit (PAT) of Rs 187.14 Cr are the headline figures. The results date of 26 October 2026 marks when these consolidated results reached NSE and BSE, and Eris Lifesciences Q2 Results FY27 form the base for everything below.

This results analysis of Eris Lifesciences Q2 Results walks through the financial highlights, the business drivers disclosed for the quarter, the outlook for FY27 and the risks worth tracking. The highlights table comes first, and the Univest Screener carries the same figures for readers who want to compare other companies.

Click Here – Get Free Investment Predictions

Eris Lifesciences Q2 Results FY27: Financial Highlights

Metric	Q2 FY27 (Sep 26)	Q2 FY26 (Sep 25)	YoY Change
Revenue	Rs 892.37 Cr	Rs 792.41 Cr	+12.61% YoY
Operating Profit	Rs 309.35 Cr	Rs 288.21 Cr	+7.33% YoY
Net Profit (PAT)	Rs 187.14 Cr	Rs 134.47 Cr	+39.17% YoY

Source: company filing for Eris Lifesciences Q2 Results FY27, 26 October 2026. Figures in Rs Crore, Consolidated basis.

Key Takeaways from Eris Lifesciences Q2 Results: What Stands Out

• Revenue of Rs 892.37 Cr grew 12.61% YoY from Rs 792.41 Cr in the same quarter last year.
• Net profit of Rs 187.14 Cr rose 39.17% YoY from Rs 134.47 Cr, a faster pace of YoY growth than revenue.
• Operating Profit of Rs 309.35 Cr compares with Rs 288.21 Cr a year earlier, a rise of 7.33% YoY.
• Net profit margin of 21.0% compares with 17.0% in the comparison quarter, a gain that frames Eris Lifesciences Q2 Results FY27.
• Debt at 0.59 times total assets in FY26 is the headline risk, which the performance analysis below sets beside the growth figures.

Eris Lifesciences Q2 Results FY27: Performance Analysis

Eris Lifesciences Q2 Results FY27 show Consolidated revenue of Rs 892.37 Cr against Rs 792.41 Cr a year earlier, a YoY growth of 12.61%. Net profit climbed 39.17% to Rs 187.14 Cr from Rs 134.47 Cr, while Operating Profit moved from Rs 288.21 Cr to Rs 309.35 Cr, up 7.33%.

The three growth rates differ in size. Net profit grew 39.17% YoY, revenue grew 12.61% and Operating Profit grew 7.33%. The supplied data confirms the movement but does not establish the specific cause, so Eris Lifesciences Q2 Results FY27 are best read through the disclosed drivers rather than assumptions.

For anyone comparing quarterly results across periods, the useful checks are whether revenue growth holds, how net profit behaves against it and whether the margin gain persists. The Eris Lifesciences Q2 Results become easier to place once later disclosures arrive, which is where the results analysis turns to the business factors.

Check the Univest Screener for live results data

Key Business Factors This Quarter

Revenue Growth – The results analysis starts with revenue, which grew 12.61% YoY to Rs 892.37 Cr in the latest quarter. This Consolidated revenue is the starting point for the profit lines reported with Eris Lifesciences Q2 Results FY27.

Net Profit Margin – Net profit margin improved to 21.0% from 17.0% in the comparison quarter, and net profit rose 39.17% YoY to Rs 187.14 Cr. These quarterly results show profit growing faster than revenue.

Return on Equity – Return on equity was 19.23% in FY26, the latest full-year ratio shown alongside the quarter. It gives context to the net profit of Rs 187.14 Cr without implying what any later quarter will deliver.

FY27 Outlook After Eris Lifesciences Q2 Results

FY27 full-year results will depend on how the coming quarters build on this one. Eris Lifesciences Q2 Results FY27 give a reference point of Rs 892.37 Cr in revenue and Rs 187.14 Cr in net profit, and the next declarations will show whether the YoY growth of 12.61% in revenue and 39.17% in net profit carries forward.

The results analysis for FY27 should also track margin and returns. Net profit margin moved to 21.0% from 17.0%, and return on equity stood at 19.23% in FY26. Later quarterly net profit figures will show how these ratios settle, which leads into the risks that the same numbers carry.

Key Risks to Watch After Eris Lifesciences Q2 Results FY27

Debt Levels

Debt is high at 0.59 times total assets in FY26. Even with net profit up 39.17% YoY in Eris Lifesciences Q2 Results FY27, the debt level is a balance sheet fact that investors can track in later filings.

Net Profit Volatility

Quarterly net profit has been volatile, ranging from Rs 99.72 Cr to Rs 281.61 Cr over the last 5 quarters. A single quarter of YoY growth therefore needs to be read against that wider range.

Rising Debt-to-Assets Ratio

Debt-to-assets rose from 0.02 in FY22 to 0.59 in FY26. Following this ratio through the remaining FY27 quarters will show whether the trend continues or eases alongside the profit growth reported this quarter.

Download the Univest iOS App or Univest Android App to track quarterly results as they are declared.

Conclusion

Eris Lifesciences Q2 Results FY27 report Consolidated revenue of Rs 892.37 Cr, up 12.61% YoY, and net profit of Rs 187.14 Cr, up 39.17% YoY. These quarterly results arrive with debt and profit-range risks that sit beside the growth. Readers following Eris Lifesciences Q2 Results on the Univest app should consult a SEBI-registered advisor before acting.

Frequently Asked Questions on Eris Lifesciences Q2 Results FY27

What are Eris Lifesciences Q2 Results FY27?

Ans. Eris Lifesciences Q2 Results FY27 cover the July to September 2026 quarter on a Consolidated basis, with revenue of Rs 892.37 Cr and net profit of Rs 187.14 Cr, which the Quick Answer and highlights summarise.

What is the results date for Eris Lifesciences Q2 Results FY27?

Ans. Eris Lifesciences announced its quarterly results on 26 October 2026, covering the July to September 2026 quarter, so the results date anchors every comparison made in the opening section of this article.

What revenue was reported in Eris Lifesciences Q2 Results FY27?

Ans. Eris Lifesciences reported Consolidated revenue of Rs 892.37 Cr in Q2 FY27, compared with Rs 792.41 Cr a year earlier, as the Financial Highlights table shows alongside the other reported figures.

What net profit was reported in Eris Lifesciences Q2 Results FY27?

Ans. Eris Lifesciences Q2 Results FY27 show net profit of Rs 187.14 Cr against Rs 134.47 Cr a year ago, which means the Key Takeaways section can place profit growth ahead of revenue growth.

How much YoY growth did revenue show in Eris Lifesciences Q2 Results FY27?

Ans. Revenue showed YoY growth of 12.61% in Eris Lifesciences Q2 Results FY27, rising from Rs 792.41 Cr to Rs 892.37 Cr, a movement that the Performance Analysis section examines in more detail.

Did net profit rise or fall in Eris Lifesciences Q2 Results?

Ans. Net profit rose in Eris Lifesciences Q2 Results, up 39.17% YoY to Rs 187.14 Cr, while revenue grew 12.61%, so the Performance Analysis section compares the two growth rates side by side.

What was the Operating Profit in Eris Lifesciences Q2 Results FY27?

Ans. Operating Profit in Eris Lifesciences Q2 Results FY27 was Rs 309.35 Cr compared with Rs 288.21 Cr a year earlier, a rise of 7.33% YoY, as covered under Key Takeaways.

Are Eris Lifesciences Q2 Results consolidated results or standalone results?

Ans. Eris Lifesciences Q2 Results are reported here on a Consolidated basis, so the consolidated results figures of Rs 892.37 Cr revenue and Rs 187.14 Cr net profit apply, as noted in the opening paragraphs.

What business factors shaped Eris Lifesciences Q2 Results FY27?

Ans. Disclosed factors include revenue growth of 12.61% YoY, a net profit margin of 21.0% against 17.0%, and return on equity of 19.23% in FY26, all covered under Key Business Factors This Quarter.

What are the key risks after Eris Lifesciences Q2 Results FY27?

Ans. The listed risks are debt at 0.59 times total assets in FY26, quarterly net profit ranging from Rs 99.72 Cr to Rs 281.61 Cr, and debt-to-assets rising from 0.02 in FY22, detailed under Key Risks.

What is the outlook after Eris Lifesciences Q2 Results?

Ans. FY27 full-year results will depend on the coming quarters, with Rs 892.37 Cr revenue and Rs 187.14 Cr net profit as the reference point, as explained in the FY27 Outlook section of this article.

Where can I find the complete Eris Lifesciences Q2 Results FY27 data?

Ans. The complete data sits in the Financial Highlights table and on the Univest Screener, where Eris Lifesciences Q2 Results FY27 can be compared with the same quarter last year, as the Conclusion also notes.